Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H27Cl2N5O3S |
| Molecular Weight | 572.506 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](N\C(=N/S(=O)(=O)C1=CC=C(Cl)C=C1)N2C[C@@H](C(=N2)C3=CC=C(Cl)C=C3)C4=CC=CC=C4)C(N)=O
InChI
InChIKey=GTCSIQFTNPTSLO-RPWUZVMVSA-N
InChI=1S/C27H27Cl2N5O3S/c1-17(2)24(26(30)35)31-27(33-38(36,37)22-14-12-21(29)13-15-22)34-16-23(18-6-4-3-5-7-18)25(32-34)19-8-10-20(28)11-9-19/h3-15,17,23-24H,16H2,1-2H3,(H2,30,35)(H,31,33)/t23-,24+/m1/s1
| Molecular Formula | C27H27Cl2N5O3S |
| Molecular Weight | 572.506 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease. | 2020-01 |
|
| Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis. | 2019-12 |
|
| Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis. | 2019-06-04 |
|
| Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin-1/Mechanistic Target of Rapamycin Complex 2 and 5'Adenosine Monophosphate-Activated Protein Kinase Signaling. | 2019-04 |
|
| Identification of novel mouse and rat CB1R isoforms and in silico modeling of human CB1R for peripheral cannabinoid therapeutics. | 2019-03 |
|
| Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy. | 2018-02 |
|
| Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling. | 2017-10 |
|
| Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo. | 2017-08 |
|
| Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d3 )butanamide-d5 , octadeuterated JD5037. | 2017-08 |
|
| Amplitude-selective filtering for remote-PPG. | 2017-03-01 |
|
| Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. | 2016-12 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 22:12:12 GMT 2025
by
admin
on
Tue Apr 01 22:12:12 GMT 2025
|
| Record UNII |
ENZ75DG2Z6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ENZ75DG2Z6
Created by
admin on Tue Apr 01 22:12:13 GMT 2025 , Edited by admin on Tue Apr 01 22:12:13 GMT 2025
|
PRIMARY | |||
|
1392116-14-1
Created by
admin on Tue Apr 01 22:12:13 GMT 2025 , Edited by admin on Tue Apr 01 22:12:13 GMT 2025
|
PRIMARY | |||
|
66553204
Created by
admin on Tue Apr 01 22:12:13 GMT 2025 , Edited by admin on Tue Apr 01 22:12:13 GMT 2025
|
PRIMARY | |||
|
DTXSID301030409
Created by
admin on Tue Apr 01 22:12:13 GMT 2025 , Edited by admin on Tue Apr 01 22:12:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->INVERSE AGONIST | |||
|
|
METABOLIC ENZYME -> INHIBITOR |
at 10 ?M 80% inhibition
IC50
|
